Search Results

- Novel Chromatinase™ platform could rapidly and systemically removes NETs associated with exacerbation of COVID-19 - Investigational biologic aims to treat hyperinflammation and thrombosis in COVID-19 patients, including those with Acute Respiratory Distress Syndrome (ARDS) - Neutrolis awarded competitive grant from the National Institutes of Health (NIH) - Recent study published in The Lancet EBioMedicine found NETs in COVID-19 patients

Winners of the Pfizer Golden Ticket Program announced last night during a panel discussion and networking event at Pfizer’s Cambridge, MA R&D site

The company announced that Neutrolis and Remora Therapeutics are the winners of Bristol-Myers Squibb’s 2017 Golden Tickets for LabCentral.

Sanofi’s Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on April 30, 2024, the renewal of the terms of office of Rachel Duan and Lise Kingo and the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.

On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area.

There are hundreds, even thousands of biotech and pharmaceutical companies.